(Q66404060)
Statements
An Open-Label, Phase 2 Efficacy Study With Window of Opportunity Immune Assessment of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) (English)
0 references
6 July 2016
0 references
June 2020
0 references
45
0 references
18 year
0 references